Springwell Veterinary Surgery has been transferred to an Employee Ownership Trust
Springwell Veterinary Surgery has become employee owned after transferring into an Employee Ownership Trust (EOT).
Located in a purpose-built, modern facility in Tring, Hertfordshire, UK, Springwell Veterinary Surgery is a well-established and highly regarded small animal practice. The practice employs a team of approximately 25 staff members.
The shareholders have decided to transfer the company to an EOT, allowing employees to benefit from the future growth of the business. EOTs, created by the UK government in 2014, give business owners the opportunity to sell their shares to an employee-owned trust without incurring capital gains tax.
Oaklins S&W, one of Oaklins’ member firms in the UK, worked with the shareholders of Edendene Limited, trading as Springwell Veterinary Surgery, to deliver a successful transfer to an Employee Ownership Trust.
Contacter l'équipe de la transaction
Transactions connexes
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
En apprendre plusbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
En apprendre plusBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
En apprendre plus